Cellular senescence is a state of irreversible cell-cycle arrest triggered by various forms of cellular stress, including DNA damage, telomere shortening, oncogenic activation, and oxidative stress. Originally characterized as a tumor-suppressive mechanism, cellular senescence has emerged over the past decade as a major driver of organismal aging and a contributing factor to the pathogenesis of neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [frontotemporal dementia](/diseases/frontotemporal-dementia).
Senescent cells accumulate in the aging brain and in disease-affected regions where they exert deleterious effects through two principal mechanisms: the loss of cellular function (cells that would normally support tissue homeostasis enter a permanently arrested state) and the acquisition of a pro-inflammatory secretory phenotype. This secretory program, known as the senescence-associated secretory phenotype (SASP), produces a complex cocktail of cytokines, chemokines, growth factors, matrix metalloproteinases, and extracellular vesicles that drive chronic [neuroinflammation](/mechanisms/microglia-neuroinflammation), disrupt synaptic function, impair neurogenesis, and spread senescence to neighboring cells through paracrine signaling [@wiley2019].
Cellular senescence is a state of irreversible cell-cycle arrest triggered by various forms of cellular stress, including DNA damage, telomere shortening, oncogenic activation, and oxidative stress. Originally characterized as a tumor-suppressive mechanism, cellular senescence has emerged over the past decade as a major driver of organismal aging and a contributing factor to the pathogenesis of neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [frontotemporal dementia](/diseases/frontotemporal-dementia).
Senescent cells accumulate in the aging brain and in disease-affected regions where they exert deleterious effects through two principal mechanisms: the loss of cellular function (cells that would normally support tissue homeostasis enter a permanently arrested state) and the acquisition of a pro-inflammatory secretory phenotype. This secretory program, known as the senescence-associated secretory phenotype (SASP), produces a complex cocktail of cytokines, chemokines, growth factors, matrix metalloproteinases, and extracellular vesicles that drive chronic [neuroinflammation](/mechanisms/microglia-neuroinflammation), disrupt synaptic function, impair neurogenesis, and spread senescence to neighboring cells through paracrine signaling [@wiley2019].
The therapeutic targeting of senescent cells using senolytic drugs (agents that selectively induce apoptosis in senescent cells) or senomorphic agents (compounds that suppress the SASP without killing senescent cells) represents one of the most actively investigated frontiers in neurodegenerative disease research. Early-phase clinical trials are now evaluating senolytics in human subjects with Alzheimer's disease and related conditions [@ochab2024].
The DNA damage response (DDR) is the central trigger of cellular senescence in post-mitotic tissues such as the brain. Persistent DNA lesions—whether arising from oxidative damage, replication stress, or environmental genotoxins—activate the ATM/ATR kinase cascade, which stabilizes the tumor suppressor protein p53. Activated p53 transcriptionally upregulates p21 (CDKN1A), which inhibits cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase 4/6 (CDK4/6), leading to hypophosphorylation of the retinoblastoma protein (Rb) and permanent G1 cell-cycle arrest [@bhat2012].
Unlike transient cell-cycle arrest, which allows cells to repair DNA damage and resume proliferation, senescence-associated arrest is irreversible. The permanence of senescence depends on the epigenetic silencing of cell-cycle genes through the formation of senescence-associated heterochromatin foci (SAHF), which compact chromatin and suppress proliferation-promoting transcripts [@hernandezsegura2018].
In neurons, which are terminally differentiated and do not normally replicate, DNA damage and DDR activation trigger a senescence-like state characterized by SASP factor secretion, mitochondrial dysfunction, and increased expression of cell-cycle regulators despite the absence of cell division. This phenomenon, sometimes termed "senescence without proliferation," has been documented in Alzheimer's disease and Parkinson's disease brain tissue and is associated with cognitive decline and motor dysfunction [@baker2018].
Two interconnected tumor suppressor pathways mediate the canonical senescence arrest:
p53/p21 pathway (DNA damage sensor):
DNA damage → ATM/ATR activation → CHK1/CHK2 → p53 phosphorylation → p21 (CDKN1A) transcription → CDK2 inhibition → Rb hypophosphorylation → G1 arrest [@bhat2012].
p16INK4a/Rb pathway (stress sensor):
Chronic stress → p16INK4a (CDKN2A) upregulation → CDK4/6 inhibition → Rb hypophosphorylation → G1 arrest [@sharpless2015].
The p16INK4a protein is widely used as the most reliable molecular marker of cellular senescence in aging and disease tissues. In the aging brain, p16INK4a-positive cells increase dramatically, accounting for a significant fraction of microglia, astrocytes, and endothelial cells. In Alzheimer's disease and Parkinson's disease brains, p16INK4a expression is elevated in specific regions vulnerable to neurodegeneration, including the hippocampus, substantia nigra pars compacta, and prefrontal cortex [@mathur2016].
Mitochondrial dysfunction is both a trigger and a consequence of cellular senescence. Senescent cells exhibit a characteristic "senomorphic" phenotype characterized by reduced mitochondrial membrane potential, increased mitochondrial reactive oxygen species (ROS) production, and impaired mitochondrial dynamics. The resulting oxidative stress damages nuclear and mitochondrial DNA, perpetuating the DDR and reinforcing the senescence state [@hernandezsegura2018].
A key metabolic feature of senescent cells is the decline of nicotinamide adenine dinucleotide (NAD+), which supports sirtuin deacetylase activity and mitochondrial function. NAD+ depletion during senescence impairs the activity of SIRT1, SIRT3, and SIRT6, deacetylases that normally protect against oxidative stress and promote DNA repair. Restoring NAD+ levels using nicotinamide riboside or nicotinamide mononucleotide has been shown to reduce senescent burden and improve tissue function in preclinical models of aging and neurodegeneration.
The mechanistic target of rapamycin (mTOR) plays a central role in regulating the SASP. The mTOR pathway integrates signals from growth factors, nutrients, and cellular energy status to control protein synthesis, autophagy, and cellular metabolism. In senescent cells, mTOR activity drives the translation of SASP-related mRNAs, particularly those encoding interleukin-6 (IL-6), interleukin-8 (IL-8), and other cytokines [@laberge2015].
Rapamycin, an mTOR inhibitor, suppresses the SASP by reducing translation of SASP components without affecting the cell-cycle arrest machinery. This "senomorphic" property makes rapamycin an attractive candidate for mitigating the harmful effects of senescence without eliminating senescent cells directly. However, the immunosuppressive effects of rapamycin complicate its application in the context of neurodegenerative disease, where microglial-mediated neuroinflammation plays a complex and context-dependent role.
Senescence induction in the brain is closely linked to the hallmark proteinopathies of Alzheimer's disease and Parkinson's disease:
In Alzheimer's disease, amyloid-beta oligomers and hyperphosphorylated tau have been shown to induce senescence in neurons, astrocytes, and microglia. Amyloid-beta triggers DNA damage and DDR activation through oxidative stress pathways. Tau pathology, particularly in its fibrillar form, induces mitochondrial dysfunction and ER stress that activate senescence pathways. Conversely, senescent glia contribute to amyloid-beta accumulation through impaired phagocytosis and to tau pathology through SASP-mediated spread of protein aggregation [@schneider2024].
In Parkinson's disease, alpha-synuclein aggregates directly induce senescence in dopaminergic neurons of the substantia nigra pars compacta. Oxidative stress from mitochondrial Complex I dysfunction, a central feature of sporadic PD, further drives senescence. In cellular and animal models, alpha-synuclein pre-formed fibrils induce p16INK4a and p21 expression, SASP factor secretion, and mitochondrial fragmentation—all hallmarks of senescence [@chinta2020].
The SASP is the principal effector mechanism by which senescent cells drive tissue dysfunction. First systematically described by Campisi and colleagues in 2008, the SASP encompasses a diverse array of secreted factors [@coppe2008]:
The SASP creates a self-reinforcing cycle of neuroinflammation. SASP factors activate the NF-κB and STAT3 transcription pathways in neighboring microglia and astrocytes, amplifying their pro-inflammatory responses. This produces a feedforward loop in which inflammatory signaling induces further senescence in adjacent cells, progressively expanding the pro-inflammatory microenvironment throughout affected brain regions.
IL-6, a dominant SASP component, activates astrocytes in a reactive state that promotes synaptic dysfunction and impaired glutamate uptake. IL-1β contributes to excitotoxicity by enhancing NMDA receptor activity. TNF-α directly stimulates amyloidogenic processing of the amyloid precursor protein (APP), increasing amyloid-beta production while simultaneously impairing microglial amyloid clearance [@wiley2019].
A critical property of the SASP is its capacity to induce senescence in neighboring healthy cells—a phenomenon termed the "senescence bystandander effect" or "paracrine senescence." SASP factors including TGF-β, IL-1α, CXCL1, and extracellular vesicles can transfer the senescence phenotype to cells that were previously healthy. In the brain, this propagation mechanism means that even a small initial burden of senescent cells can progressively spread the senescence state through glial networks, accelerating tissue-wide dysfunction.
Recent single-cell transcriptomic studies of Alzheimer's disease and Parkinson's disease brains have confirmed that SASP-linked gene expression programs are widespread across multiple cell types, consistent with a network-level amplification of senescence [@goro2025].
Microglia represent the largest population of senescent cells in the aging brain. Senescent microglia adopt a dystrophic morphology characterized by fragmented processes and reduced arborization, distinct from the fully activated pro-inflammatory phenotype. They exhibit elevated IL-6, TNF-α, and complement component C1q secretion, contributing to synaptic pruning dysfunction and neuronal loss. Impaired phagocytic clearance of amyloid-beta and alpha-synuclein further accelerates protein aggregation pathology.
Astrocytes undergoing senescence lose their homeostatic functions, including glutamate uptake, potassium buffering, and metabolic support of neurons. Senescent astrocytes upregulate GFAP (reactive astrogliosis) while downregulating GLT-1 (EAAT2) glutamate transporters, creating conditions favorable for excitotoxicity. They also secrete factors that promote tau hyperphosphorylation and contribute to blood-brain barrier dysfunction through MMP-mediated degradation of tight junction proteins [@tajes2024].
Oligodendrocyte precursor cells (OPCs) are highly sensitive to senescence induction. Senescent OPCs fail to differentiate into mature myelinating oligodendrocytes, contributing to the progressive white matter loss observed in both normal aging and neurodegenerative disease. The resulting demyelination impairs neuronal conduction velocity and contributes to cognitive decline.
Neurons, despite being post-mitotic, can enter a senescence-like state characterized by SASP secretion, DNA damage accumulation, and altered chromatin organization. The term "senescence-like neuronal state" distinguishes this from replicative senescence observed in dividing cells, but the functional consequences—including mitochondrial dysfunction, metabolic stress, and inflammatory signaling—are similar.
The classic histological marker of cellular senescence is senescence-associated beta-galactosidase (SA-β-gal), detected at pH 6.0 using X-gal staining. SA-β-gal activity reflects the accumulation of lysosomal β-galactosidase, which is upregulated in senescent cells due to increased lysosomal mass [@dimri1995]. However, SA-β-gal is not specific to senescence and can be positive in growth-arrested or highly metabolically active non-senescent cells.
p16INK4a immunohistochemistry provides a more specific marker of the senescence state and is detectable in paraffin-embedded brain tissue. The combination of p16INK4a positivity with SA-β-gal activity and loss of nuclear Lamin B1 provides robust confirmation of senescence in brain sections.
Other histological markers include γH2AX foci (indicating persistent DNA damage response) and senescence-associated heterochromatin foci (SAHF) visualized with DAPI staining.
At the molecular level, senescent cells exhibit characteristic gene expression signatures:
Senolytic drugs eliminate senescent cells by disrupting the anti-apoptotic pathways (senescent cell anti-apoptotic pathways, SCAPs) that allow them to survive under conditions that would kill normal cells. The BCL-2 family proteins BCL-2, BCL-xL, and BCL-w are particularly important SCAP components, and their inhibition triggers apoptosis specifically in senescent cells [@childs2015].
| Drug | Mechanism | Status |
|------|-----------|--------|
| Dasatinib + Quercetin (D+Q) | Multi-kinase inhibitor (dasatinib) + flavonoid (quercetin) targeting BCL-2 family, PI3K, serpines | Phase 2 trials in AD |
| Fisetin | Flavonoid; PI3K/AKT/mTOR inhibition, senotherapeutic | Phase 1 trials |
| Navitoclax (ABT-263) | BCL-2/BCL-xL/BCL-w inhibitor | Preclinical in neurodegeneration |
| ABT-737 | BCL-2/BCL-xL inhibitor | Preclinical |
| UBX0101 | MDM2/p53 interaction inhibitor | Phase 2 osteoarthritis (off-target) |
The combination of dasatinib (100 mg) and quercetin (1250 mg) administered intermittently (2 consecutive days every 2 weeks) has been the most extensively studied senolytic regimen in human subjects. Early trials demonstrated safety and feasibility in older adults with mild cognitive impairment, with some participants showing improvements in walking speed and cognitive function [@kirkland2019; @ochab2024].
Fisetin, a flavonoid abundant in strawberries, has senolytic activity through inhibition of PI3K, AKT, and mTOR, and has been shown to extend healthspan and lifespan in mice when administered late in life. It has advanced to early-phase human trials for Alzheimer's disease [@yousefzadeh2021].
Senomorphic agents suppress the harmful SASP without killing senescent cells, offering a potentially safer approach in contexts where complete elimination of senescent cells may be undesirable (e.g., wound healing, tissue repair):
Several clinical trials are evaluating senolytic approaches in Alzheimer's disease:
A major obstacle to senolytic therapy in neurodegenerative disease is achieving adequate central nervous system (CNS) concentrations. The blood-brain barrier (BBB) restricts the passage of most senolytic compounds. Strategies under investigation include:
In Alzheimer's disease, senescence induction is driven by multiple converging pathways:
Studies in mouse models of Alzheimer's disease (5xFAD, APP/PS1, 3xTg-AD) demonstrate that senolytic treatment with dasatinib + quercetin reduces senescent cell burden, decreases neuroinflammation, lowers amyloid-beta plaque load, and improves cognitive performance @schneider2024. Similar findings have been reported in tau-transgenic models, where senolytics reduce tau hyperphosphorylation and neurofibrillary tangle burden.
A recent longitudinal study found that individuals with higher peripheral markers of cellular senescence (p16INK4a in leukocytes, plasma SASP factors) show accelerated cognitive decline and reduced brain volume in regions affected by Alzheimer's disease @goro2025.
In Parkinson's disease, senescence is particularly prominent in dopaminergic neurons of the substantia nigra pars compacta, which are selectively vulnerable to mitochondrial dysfunction and oxidative stress. Key drivers include:
Senolytic treatment in the MPTP mouse model of PD reduces dopaminergic neuron loss, improves motor function, and decreases neuroinflammation. Combination approaches targeting both senescence and alpha-synuclein aggregation are under investigation as potentially synergistic strategies.
Cellular models of senescence in neurodegeneration include:
Animal models used in senescence and neurodegeneration research:
Recent studies have expanded the scope of senescence research in neurodegeneration:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving Cellular Senescence in Neurodegeneration discovered through SciDEX knowledge graph analysis: